Long-term survival from myocardial infarction (MI) has improved with the use of 2-adrenergic blockers (BB) and angiotensin converting enzyme inhibitors (ACEi). Acute survival from myocardial infarction (MI) has also improved in recent years due to advances in early intervention. Nonetheless, current therapy is inadequate with many patients eventually progressing to dilated heart failure. After MI, patients develop low thyroid hormone (TH) levels and growing evidence suggests they may benefit from TH treatment. After MI, there is a rapid reduction in TH function which appears to be due to increased myocardial expression of the D3 deiodinase. D3 converts T4 to inactive rT3 and T3 to inactive T2. MI-related mortality increases as THs decline and rT3 levels increase. Additionally, hypothyroidism alone can lead to dilated heart failure while promoting a maladaptive change in myocyte shape and increased interstitial collagen. Interestingly, both of these maladaptive mechanisms play an important role in post-MI remodeling of the non-infarcted myocardium and progression to dilated failure. New data from rats shows that TH treatment of MI improved left ventricular function without elevating heart rate and led to a remarkable change in myocyte shape and reduced chamber diameter/posterior wall thickness ratio. These changes should prevent or attenuate progression to dilated heart failure. This proposal will test the hypothesis that low thyroid function resulting from MI is maladaptive and TH treatment will arrest progression of chamber dilatation and failure by induction of a beneficial change in myocyte shape, reduction of interstitial fibrosis, and stimulation of microvascular growth in the non-infarcted myocardium.Signaling networks underlying these cellular changes will also be investigated.
Each aim i s designed to provide critical, clinically- relevant information about post-MI thyroid hormone treatment effects on cell and tissue remodeling, LV function, and long-term outcome that is not currently available. Much of the information to be obtained cannot be collected from human trials for ethical reasons. For instance, the effects of thyroid hormone treatment alone and in the background of standard therapy (ACE inhibitors, 2-blockers) will be examined. These animal data should provide important insight for interpretation of their clinical results and should also be of predictive value in planning future long-term treatment studies.

Public Health Relevance

New evidence indicates that myocardial infarction triggers low thyroid function in cardiac tissue and restoration of normal thyroid function may beneficially improve remodeling and outcome. The proposed experiments in thyroid hormone treated rats with myocardial infarction will provide key cellular information and insight needed to move forward with optimal design and implementation of clinical trials in this area.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Schwartz, Lisa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York Institute of Technology
Other Basic Sciences
Schools of Osteopathic Medicine
Old Westbury
United States
Zip Code
Rajagopalan, Viswanathan; Zhang, Youhua; Pol, Christine et al. (2017) Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury. Front Physiol 8:225
Samuel, Sherin; Zhang, Kuo; Tang, Yi-Da et al. (2017) Triiodothyronine Potentiates Vasorelaxation via PKG/VASP Signaling in Vascular Smooth Muscle Cells. Cell Physiol Biochem 41:1894-1904
Rajagopalan, Viswanathan; Zhang, Youhua; Ojamaa, Kaie et al. (2016) Safe Oral Triiodo-L-Thyronine Therapy Protects from Post-Infarct Cardiac Dysfunction and Arrhythmias without Cardiovascular Adverse Effects. PLoS One 11:e0151413
Weltman, Nathan Y; Pol, Christine J; Zhang, Youhua et al. (2015) Long-term physiological T3 supplementation in hypertensive heart disease in rats. Am J Physiol Heart Circ Physiol 309:H1059-65
Bollinger, Stephen S; Weltman, Nathen Y; Gerdes, A Martin et al. (2015) T3 supplementation affects ventilatory timing & glucose levels in type 2 diabetes mellitus model. Respir Physiol Neurobiol 205:92-8
Zhang, Youhua; Dedkov, Eduard I; Lee 3rd, Bianca et al. (2014) Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model. J Card Fail 20:1012-9
Zhang, Youhua; Dedkov, Eduard I; Teplitsky, Diana et al. (2013) Both hypothyroidism and hyperthyroidism increase atrial fibrillation inducibility in rats. Circ Arrhythm Electrophysiol 6:952-9
Chen, Yue-Feng; Weltman, Nathan Y; Li, Xiang et al. (2013) Improvement of left ventricular remodeling after myocardial infarction with eight weeks L-thyroxine treatment in rats. J Transl Med 11:40
Weltman, Nathan Y; Ojamaa, Kaie; Savinova, Olga V et al. (2013) Restoration of cardiac tissue thyroid hormone status in experimental hypothyroidism: a dose-response study in female rats. Endocrinology 154:2542-52
Chen, Yue-Feng; Pottala, James V; Weltman, Nathan Y et al. (2012) Regulation of gene expression with thyroid hormone in rats with myocardial infarction. PLoS One 7:e40161